These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 21576685

  • 1. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
    Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S.
    Neurology; 2011 May 17; 76(20):1697-704. PubMed ID: 21576685
    [Abstract] [Full Text] [Related]

  • 2. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 3. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 10; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 4. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 5. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 6. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 10; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 7. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 10; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 8. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 10; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 9. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun 10; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 10. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.
    Ann Neurol; 2012 Nov 10; 72(5):779-87. PubMed ID: 23280794
    [Abstract] [Full Text] [Related]

  • 11. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
    Kleiter I, Schröder M, Lürding R, Schuierer G, Clifford DB, Bogdahn U, Steinbrecher A, Pöschl P.
    Mult Scler; 2010 Jun 10; 16(6):749-53. PubMed ID: 20453014
    [Abstract] [Full Text] [Related]

  • 12. A giant MS plaque mimicking PML during natalizumab treatment.
    Twyman C, Berger JR.
    J Neurol Sci; 2010 Apr 15; 291(1-2):110-3. PubMed ID: 20144466
    [Abstract] [Full Text] [Related]

  • 13. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 14. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 15. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.
    J Neurovirol; 2015 Dec 28; 21(6):637-44. PubMed ID: 25771865
    [Abstract] [Full Text] [Related]

  • 16. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 17. [Monoclonal antibodies in multiple sclerosis].
    Papeix C, Lubetzki C.
    Med Sci (Paris); 2009 Dec 01; 25(12):1113-5. PubMed ID: 20035688
    [Abstract] [Full Text] [Related]

  • 18. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.
    Neurology; 2011 Feb 08; 76(6):574-6. PubMed ID: 21300973
    [No Abstract] [Full Text] [Related]

  • 19. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 20. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
    Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME.
    J Autoimmun; 2008 Apr 14; 30(1-2):90-8. PubMed ID: 18191544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.